Literature DB >> 17690946

Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis.

K Wada-Isoe1, K Michio, K Imamura, K Nakaso, M Kusumi, H Kowa, K Nakashima.   

Abstract

Dementia with Lewy bodies (DLB) is the second most common senile degenerative dementia after Alzheimer's disease (AD). The presentation of overlapping symptoms between these two disorders leads to difficulties in the determination of clinical entities. Serum samples were subjected to surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) analysis in order to identify a diagnostic marker for DLB. Four putative protein peaks (m/z 3,883, 4,964, 7,761 and 10,534) were differentially expressed in DLB patients compared to AD patients and control subjects. Receiver operating characteristics (ROC) analysis of a multivariate logistic model of the combination of three peaks (m/z 3,883, 7,761 and 10,534) exhibited the highest discriminatory ability of DLB subjects from non-DLB subjects with a sensitivity of 83.3%, a specificity of 95.8%, a positive predictive value of 90.9% and a negative predictive value of 92.0%. SELDI-TOF MS profiling, therefore, has revealed a serum signature with high diagnostic potential for DLB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690946     DOI: 10.1007/s00702-007-0794-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  16 in total

Review 1.  Biomarker discovery from body fluids using mass spectrometry.

Authors:  Ana Villar-Garea; Matthias Griese; Axel Imhof
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-11-09       Impact factor: 3.205

2.  A serum protein signature with high diagnostic value in bacterial endocarditis: results from a study based on surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Florence Fenollar; Anthony Goncalves; Benjamin Esterni; Said Azza; Gilbert Habib; Jean-Paul Borg; Didier Raoult
Journal:  J Infect Dis       Date:  2006-10-11       Impact factor: 5.226

3.  Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.

Authors:  Dominique de Seny; Marianne Fillet; Marie-Alice Meuwis; Pierre Geurts; Laurence Lutteri; Clio Ribbens; Vincent Bours; Louis Wehenkel; Jacques Piette; Michel Malaise; Marie-Paule Merville
Journal:  Arthritis Rheum       Date:  2005-12

4.  Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.

Authors:  S Minoshima; N L Foster; A A Sima; K A Frey; R L Albin; D E Kuhl
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

5.  Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

Authors:  Mikio Shoji; Etsuro Matsubara; Tetsuro Murakami; Yasuhiro Manabe; Koji Abe; Mitsuyasu Kanai; Masaki Ikeda; Yasushi Tomidokoro; Masami Shizuka; Mitsunori Watanabe; Masakuni Amari; Koji Ishiguro; Takeshi Kawarabayashi; Yasuo Harigaya; Koichi Okamoto; Tsuyosi Nishimura; Yu Nakamura; Masatoshi Takeda; Katsuya Urakami; Yoshiki Adachi; Kenji Nakashima; Hiroyuki Arai; Hidetada Sasaki; Kazutomi Kanemaru; Hiroshi Yamanouchi; Yasuji Yoshida; Kunihiro Ichise; Kuniaki Tanaka; Makoto Hamamoto; Hideki Yamamoto; Takeyuki Matsubayashi; Hiroshi Yoshida; Hiromasa Toji; Shigenobu Nakamura; Shunsaku Hirai
Journal:  Neurobiol Aging       Date:  2002 May-Jun       Impact factor: 4.673

6.  Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.

Authors:  Yasunori Mito; Kazuto Yoshida; Ichiro Yabe; Kenichi Makino; Makoto Hirotani; Kunio Tashiro; Seiji Kikuchi; Hidenao Sasaki
Journal:  Clin Neurol Neurosurg       Date:  2005-01-19       Impact factor: 1.876

7.  A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.

Authors:  M Yoshita; J Taki; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

8.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

9.  Identification of potential CSF biomarkers in ALS.

Authors:  G M Pasinetti; L H Ungar; D J Lange; S Yemul; H Deng; X Yuan; R H Brown; M E Cudkowicz; K Newhall; E Peskind; S Marcus; L Ho
Journal:  Neurology       Date:  2006-02-15       Impact factor: 9.910

Review 10.  Dementia with Lewy bodies.

Authors:  Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L Lopez; João Carlos Machado; John O'Brien; Jeremy Playfer; Wayne Reid
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

View more
  5 in total

1.  U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease.

Authors:  Bing Bai; Chadwick M Hales; Ping-Chung Chen; Yair Gozal; Eric B Dammer; Jason J Fritz; Xusheng Wang; Qiangwei Xia; Duc M Duong; Craig Street; Gloria Cantero; Dongmei Cheng; Drew R Jones; Zhiping Wu; Yuxin Li; Ian Diner; Craig J Heilman; Howard D Rees; Hao Wu; Li Lin; Keith E Szulwach; Marla Gearing; Elliott J Mufson; David A Bennett; Thomas J Montine; Nicholas T Seyfried; Thomas S Wingo; Yi E Sun; Peng Jin; John Hanfelt; Donna M Willcock; Allan Levey; James J Lah; Junmin Peng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-10       Impact factor: 11.205

2.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

3.  Bridging molecular genetics and biomarkers in lewy body and related disorders.

Authors:  Gilbert J Ho; Willie Liang; Masaaki Waragai; Kazunari Sekiyama; Eliezer Masliah; Makoto Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2011-07-03

Review 4.  Biomarkers in biological fluids for dementia with Lewy bodies.

Authors:  Sebastian Schade; Brit Mollenhauer
Journal:  Alzheimers Res Ther       Date:  2014-10-16       Impact factor: 6.982

5.  Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Yuji Naito; Hiroshi Ichikawa; Satomi Akagiri; Kazuhiko Uchiyama; Tomohisa Takagi; Osamu Handa; Zenta Yasukawa; Makoto Tokunaga; Noriyuki Ishihara; Tsutomu Okubo; Jun Mukai; Makoto Ohki; Kagehiro Uchida; Toshikazu Yoshikawa
Journal:  J Clin Biochem Nutr       Date:  2015-12-08       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.